ImmuCell Corp Files 8-K: Material Definitive Agreement

TL;DR

ImmuCell signed a new deal, details TBD.

AI Summary

On November 29, 2024, ImmuCell Corporation entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement or any associated dollar amounts. The report was filed on December 2, 2024.

Why It Matters

This filing indicates a significant new agreement for ImmuCell Corporation, which could impact its business operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its implications.

Key Players & Entities

• ImmuCell Corporation (company) — Registrant
• November 29, 2024 (date) — Date of earliest event reported
• December 2, 2024 (date) — Date of report filing

FAQ

Key Financial Figures

• $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The NASDAQ

Filing Documents

• ea0223315-8k_immu.htm (8-K) — 26KB
• ea022331501ex10-1_immu.htm (EX-10.1) — 22KB
• 0001213900-24-104543.txt ( ) — 220KB
• iccc-20241129.xsd (EX-101.SCH) — 3KB
• iccc-20241129_lab.xml (EX-101.LAB) — 33KB
• iccc-20241129_pre.xml (EX-101.PRE) — 22KB
• ea0223315-8k_immu_htm.xml (XML) — 3KB

01 Entry Into a Material Definitive Agreement

Item 1.01 Entry Into a Material Definitive Agreement. On November 29, 2024, ImmuCell Corporation (the "Company") entered into an Amending Agreement (the "Amendment") with Norbrook Laboratories Limited ("Norbrook"), which Amendment amends that certain Development Services and Commercial Supply Agreement, dated September 5, 2019, by and between the Company and Norbrook (as amended to date, the "Agreement"). Pursuant to the Agreement, Norbrook provides certain formulation, aseptic filling and packaging services for the Company at its FDA-licensed facility in connection with the regulatory approval and subsequent commercial product sales of Re-Tain , the Company's purified Nisin treatment for subclinical mastitis in lactating dairy cows. The Amendment provides, among other things, that Norbrook shall complete the manufacture of current in-process inventory and that the Agreement between the Company and Norbrook shall terminate on March 31, 2026 (subject to the terms of the Agreement). The forgoing description of the Amendment is qualified in its entirety by reference to the Amendment, which is filed as Exhibit 10.1 hereto and incorporated herein by this reference.

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amending Agreement between the Company and Norbrook Laboratories Limited dated as of November 29, 2024. 104 Cover Page Interactive Data File 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: December 2, 2024 By: /s/ Michael F. Brigham Michael F. Brigham President and Chief Executive Officer 2 EXHIBIT INDEX Exhibit No. Description 10.1 Amending Agreement between the Company and Norbrook Laboratories Limited dated as of November 29, 2024. 104 Cover Page Interactive Data File 3

View Full Filing

View this 8-K filing on SEC EDGAR